Fenwick Represents DexCare in $50 Million Series B Financing

Fenwick represented DexCare, a data-driven intelligence company focused on healthcare access, in its $50 million Series B financing. The round was led by Transformation Capital and included participation from all existing investors, Kaiser Permanente, Providence Ventures, Mass General Brigham, Define Ventures, Frist Cressey Ventures and SpringRock Ventures.

DexCare will use the new funds to support and accelerate its growth with investments in product and technology innovation, customer experience and recruiting talent. More information can be obtained from the company’s announcement.

The Fenwick transaction team was led by corporate partner Michael Esquivel and included counsel Khang Tran and associate Kevin Cergol.